breast cancer
-
What a ‘War’ on Cancer Means for the Quality of Treatment Breast Cancer Patients Receive
We need more research and consideration of other approaches to cancer treatment and development of new therapies that better account for the quality of life of cancer patients.
-
Roche Forks Over $70M for Brain-Penetrating Cancer Drug Candidate
Roche is acquiring global rights to a Zion Pharma Limited drug candidate with potential applications treating breast cancer that has metastasized to the brain. The small molecule, currently in Phase 1 testing, is designed to penetrate the blood-brain barrier.
-
Payer’s Place: Dawn Maroney
Dawn Maroney, President, Markets of Alignment Health and CEO of Alignment Health Plan, to discuss how they are using technology to provide better service and care to consumers.
-
VC Identifies 3 Startups That Will Shake Up the Future of Cancer Care
Oncology Ventures recently announced investments in three cancer startups — VivorCare, Gabbi and Health Universe. The fund’s founding partner said each company demonstrated an ability to tackle a specific problem within the cancer care space, such as enabling earlier breast cancer diagnoses and providing personalized care plans for cancer survivors.
-
Gilead Sciences Drug Wins FDA Approval in Most Common Type of Breast Cancer
Gilead Sciences drug Trodelvy is now approved for treating patients whose breast cancer is classified as HR positive and HER2 negative, expanding use of the drug to a much wider group of patients. In other regulatory approval news, use of a Takeda Pharmaceutical rare disease drug has expanded to younger children.
-
Where Big Pharmas Faltered, Stemline Succeeds and Lands FDA Nod in Breast Cancer
Orserdu, a drug from Menarini Group subsidiary Stemline Therapeutics, is now approved for treating breast cancers that carry the ESR1 mutation. The drug is the first approved oral therapy from a class of therapies called selective estrogen receptor degraders (SERDs).
-
Google Partners with iCAD, Licenses Its Mammography AI Model for the First Time
Medical device manufacturer iCAD entered into a development and commercialization agreement with Google Health, in which it will integrate Google’s mammography AI technology into its suite of breast imaging AI products. The agreement marks Google’s first commercial partnership to deploy its breast imaging AI model into clinical practice.
-
Owkin’s AI solutions for breast and colorectal cancer receive European approval
The breast cancer solution will help determine which patients would benefit from targeted therapies and which patients could avoid chemotherapy. Meanwhile, the colorectal solution will be able to match patients with the most effective treatment sooner.
-
Sanofi drops out of competitive breast cancer drug race after another trial failure
Sanofi breast cancer drug amcenestrant has failed in a Phase 3 clinical trial, leading the pharmaceutical giant to discontinue all clinical development of the small molecule. The move means Sanofi is out of the competitive chase to develop a so-called “oral SERD” therapy for patients with a certain type of breast cancer.
-
Gilead claims breast cancer trial win but offers few details; drug application is filed with FDA
Gilead Sciences said it has statistically significant and clinically meaningful data from a pivotal test of its cancer drug, Trodelvy, in the most common type of breast cancer. While detailed data remain undisclosed, the company said it has filed a submission with the FDA seeking to expand the drug’s approval to include this larger group of breast cancer patients.
-
Applying Remote Patient Monitoring to Surgery Prep and Recovery, Oncology and Women’s Health
Join us to learn about the latest trends in remote monitoring and how to extend its benefits beyond chronic conditions to more patients – all while using fewer staff resources.
-
FDA approval of AstraZeneca drug is first for a new group of breast cancer patients
Enhertu, a breast cancer drug from AstraZeneca and Daiichi Sankyo, is now FDA approved for treating patients whose tumors express low levels of the protein HER2. The decision makes the infused therapy the first targeted treatment for this new category of breast cancer patients.
-
AstraZeneca, Daiichi Sankyo have high hopes for drug that goes low in breast cancer
During the annual meeting of the American Society of Clinical Oncology, AstraZeneca and Daiichi Sankyo reported pivotal clinical trial data showing that their partnered cancer drug Enhertu can treat a group of patients previously thought to be out of reach for a targeted therapy. The results suggest use of this FDA-approved drug could significantly expand to more breast cancer patients.
-
Gilead offers more detail on breast cancer drug’s trial results. Is it enough?
Gilead Sciences has more detail about breast cancer drug Trodelvy, a blockbuster hopeful it acquired two years ago. Additional data from a pivotal study were presented during the annual meeting of the American Society of Clinical Oncology and they still leave many questions unanswered.
-
Devices & Diagnostics, Artificial Intelligence, Health Tech
FDA clears wearable 3D ultrasound for breast imaging
Startup iSono Health said its FDA-cleared automated imaging system will make personalized whole breast imaging more accessible to women worldwide and could help improve breast cancer diagnosis.
-
BioPharma, Health Tech, Patient Engagement
INVEST Pitch Perfect winner: Athelo helps patients navigate cancer journey
Athelo Health’s software is a personal coach that supports women with breast and gynecological cancers. The startup was judged co-winner in the pharmatech category during the recent MedCity INVEST conference in Chicago.
-
Cancer biotech Pheast unveils $76M to expand immunotherapy’s menu to new targets
Biotech startup Pheast Therapeutics is out of stealth taking a tack similar to that of cancer immunotherapy company Forty Seven, also a spinout from the Stanford University lab of Irving Weissman. While both companies get immune cells to eat tumors, Pheast’s technology has the potential to take the approach to a broader range of cancer types including those that have historically resisted immunotherapy.
Promoted
Payer’s Place: Dr. Anil Singh
Dr. Anil Singh shares his insights into the strategies employed by the organization to identify the most effective digital solutions for their members.
Promoted
Discover the Next-Gen Platform for Integrated Collaborative Care
Beyond EHRs and digital front doors, reducing the gaps in patient care journeys.
